Non-annotated gene. Preliminary data : if you are an author who wish to write a full paper/card on this gene, contribute in submission tool
Other Information
Locus ID:
NCBI: 53616
MIM: 603709
HGNC: 201
Ensembl: ENSG00000008277
Variants:
dbSNP: 53616
ClinVar: 53616
TCGA: ENSG00000008277
COSMIC: ADAM22
RNA/Proteins
Expression (GTEx)
Pathways
| Pathway | Source | External ID |
|---|---|---|
| Developmental Biology | REACTOME | R-HSA-1266738 |
| LGI-ADAM interactions | REACTOME | R-HSA-5682910 |
References
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 38518731 | 2024 | ADAM22 acts as a novel predictive biomarker for unfavorable prognosis and facilitates metastasis via PI3K/AKT signaling pathway in nasopharyngeal carcinoma. | 0 |
| 38518731 | 2024 | ADAM22 acts as a novel predictive biomarker for unfavorable prognosis and facilitates metastasis via PI3K/AKT signaling pathway in nasopharyngeal carcinoma. | 0 |
| 35373813 | 2022 | Biallelic ADAM22 pathogenic variants cause progressive encephalopathy and infantile-onset refractory epilepsy. | 8 |
| 35373813 | 2022 | Biallelic ADAM22 pathogenic variants cause progressive encephalopathy and infantile-onset refractory epilepsy. | 8 |
| 31627033 | 2020 | LGI3 is secreted and binds to ADAM22 via TRIF-dependent NF-κB pathway in response to LPS in human keratinocytes. | 4 |
| 33208158 | 2020 | ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis. | 4 |
| 31627033 | 2020 | LGI3 is secreted and binds to ADAM22 via TRIF-dependent NF-κB pathway in response to LPS in human keratinocytes. | 4 |
| 33208158 | 2020 | ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis. | 4 |
| 29670100 | 2018 | Structural basis of epilepsy-related ligand-receptor complex LGI1-ADAM22. | 31 |
| 30278449 | 2018 | miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22. | 24 |
| 29670100 | 2018 | Structural basis of epilepsy-related ligand-receptor complex LGI1-ADAM22. | 31 |
| 30278449 | 2018 | miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22. | 24 |
| 27760137 | 2016 | Secretion-Positive LGI1 Mutations Linked to Lateral Temporal Epilepsy Impair Binding to ADAM22 and ADAM23 Receptors. | 8 |
| 27760137 | 2016 | Secretion-Positive LGI1 Mutations Linked to Lateral Temporal Epilepsy Impair Binding to ADAM22 and ADAM23 Receptors. | 8 |
| 23810013 | 2013 | ADAM22 as a prognostic and therapeutic drug target in the treatment of endocrine-resistant breast cancer. | 11 |
Citation
Dessen P
ADAM22 (ADAM metallopeptidase domain 22)
Atlas Genet Cytogenet Oncol Haematol. 2007-04-01
Online version: http://atlasgeneticsoncology.org/gene/47115/adam22
